Live Breaking News & Updates on கல்லீரல் மாற்றுத்திறனாளிகள்|Page 3

Stay updated with breaking news from கல்லீரல் மாற்றுத்திறனாளிகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at .
Metacrine, Inc.March 11, 2021 GMT
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that final results from the company’s Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist in development for the treatment of non-alcoholic steatohepatitis (NASH), will be presented as a distinguished abstract at the 2021 NASH-TAG Conference. The conference is taking place March 11-13, 2021 in Park City, Utah and virtually on-line. ....

United States , Park City , Kyoung Jin Lee , Jonathan Lee , Richard Pencek , Steve Kunszabo , Hubertc Chen , Exchange Commission , Metacrine Inc , Non Alcoholic Steatohepatitis , Private Securities Litigation Reform Act , Quarterly Report , Corporate News , Drug Trials , Products And Services , Government Regulations , Clinical Trials , Diagnosis And Treatment , Liver Transplants , Product Testing , Diseases And Conditions , Government And Politics , Medical Research , Liver Disease , Organ Transplants , Globe Newswire ,

Homozygous Familial Hypercholesterolemia Epidemiology Forecast to 2030


Press release content from Business Wire. The AP news staff was not involved in its creation.
Homozygous Familial Hypercholesterolemia Epidemiology Forecast to 2030 - ResearchAndMarkets.com
February 5, 2021 GMT
DUBLIN (BUSINESS WIRE) Feb 5, 2021
This ‘Homozygous familial hypercholesterolemia (HoFH) - Epidemiology Forecast - 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Homozygous familial hypercholesterolemia (HoFH) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
ADVERTISEMENT
Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Homozygous Familial Hypercholesterolemia (HoFH), Diagnosed Prevalence of Homozygous Familial Hypercholesterolemia (HoFH) and Mutation-specific Distribution of Homozygous Familial Hypercholesterolemia (HoFH) in the 7MM market cov ....

United States , United Kingdom , Proprotein Convertase Subtilin Kexin , Laura Wood , E St Office Hours Call , Office Hours Call , Familial Hypercholesterolemia , Homozygous Familial Hypercholesterolemia , Diagnosed Prevalence , Mutation Specific Distribution , Detailed Epidemiology , Proprotein Convertase , Years Forecast , Topics Covered , Senior Press , Free Call , Hours Call , Business Wire , Cardiovascular Disease , Medical Research , Liver Transplants , Western Europe , Vascular Disease , Diseases And Conditions , Diagnosis And Treatment , Organ Transplants ,